This invention relates to spacer less carbon nanotubes for drug delivery in the treatment of cancer.
It is known that carbon nanotubes (CNTs) have been developed as Nan vehicles for targeted drug delvers of various diseases. The development of functionalized carbon nanotube (f-CNTs) Nan vehicles by covalent bond approach involves an amino-spacer or thiol-spacer and polyethylene glycol (PEG) for the attachment of drugs on the f-CNTs. To overcome the spacer problem, it is essential that the drug molecules should directly be covalently bonded to f-CNT to reduce the diameter of the Nan vectors and pave the way for easy penetration through the cage barrier.
In the present invention folic acid (ttavt). cyst amine, fluoresced isothiocyanate, PD98059 (DNA Inhibitor) and doxorubicin (anti-cancer drug) are used for the preparation of spacer less multiwalled carbon nanotube (MWNTs) Nan vectors. The elimination of the spacers and attachment of the drug and folic acid to the nanotubes facilitates drug delivery directly to the

diseased cells, making all the difference between failure and success.
This invention therefore relates to the attachment of the drug on the surface of the f-CNTs without spacers. Folic acid, Cyst amine, Fluoresce in Isothiocyanate (FITC), PD98059 (DNA Inhibitor), Doxorubicin (anti-cancer drug) are used for the preparation of the spacer less multiwalled carbon nanotube (MWTs) Nan vectors.
Even though functionalized carbon nanotubes hold currently strong promise as novel material for the delivery of drugs, proteins, and nucleic acid, the major challenge is to overcome the barrier imposed by the cellular membrane. This invention overcomes this barrier by covalently bonding the drug molecules directly on the surface of the f-CNT without spacer This will reduce the diameter of the Nan vectors for easy penetration through the cell barrier with more drugs.

Thus the object of the present invention is to propose spacerless nanotubes on which the drug is covalently bonded on the surface of the f-CNTs, eliminating the spacer. Foci acid and cysteamine. Fluorescent Isothiocyanate (FITC), PD98059 (DNA Inhibitor) and Doxorubicin (anti-cancer drug) are covalentiy bonded to the f-CNT Nan vehicles for the preparation of spacerless multi walled carbon nanotube (MWNTs) neon vectors. The non-toxicit}' of MWNT/Cysteamine, Fluoresce in IsoThiocyamte (PJTC), PD9S059 (DNA Inhibitor) and Doxorubicin (anti-cancer drug) nanovectors was confirmed and the treatment of fibroblast with MWNT/ cysteamine. Folic acid. Fluorescein IsoThiocyanate (FITC), PD98059 (DNA Inhibitor). Doxorubicin (anti¬cancer drug) shows a significant increase in the absorbance values indicating the cell proliferation and the internalization of the nanometer were ensured by fluorescent microscopy and Raman spectrum.

The method of preparing spacerless carbon nanotubes for drug delivery in the treatment of cancer, according to this invention., composes the preparation of nanotubes m a biological buffer (50 mM) in 8 ml of H2O: adjusting the pH to 6.0 using IN NaOH or IN HCh taking 50 mM of EDC (1-ethyl -3(3-dimethylaminoprop>l) caibodimide-mediator) in 1ml of H2O, and 50 mM of NHS (N-hydroxy)' succinimide-bear ester) in 1ml of H2O; adding EDC, followed by NHS to buffer; adding Folic acid/cysteamine/ Fluorescein [soThiocyanate/PD98059 (DNA Inhibitor), Doxorubicin (anti-cancer drug); storms continuously for 6h; removing the uncoupled drugs by washing thoroughly until pH-7.0 is reached: the EDC and NHS coupling to form urea removed by washing.

The salient features of this invention are:
I. The fictionalization of carbon nanotubes (f-€Nls)
by chemical reduction method and further purification
of the f-CNTs.
2. Spacerless conjugation of drug 0n f-CNTs with
loading of folic acid (bait), calamine,
fluorescein isothiocyanate, PD98059 (DNA
Inhibitor) and doxorubicin (anti-cancer drug) on the
spacerless f-CNT8 ■
3.investigation of cell viability efficacy of folic acid
PD98059 (DNA Inhibitoi5) and doxorubicin (anti-cancer drug)
4. Durability and stability of Me acidly (bait)
oysterman, PD9S059 (DNA Inhibitor) and
doxorubicin (anti-cancer drug) on spacerless f-CNTs
5. Specificity and internalization of carbon
nanovectors in the cancer cell
7. the attachment of drug on spacerless f-CNTs is
achieved by a simple and cost effective method

We Claim:
1. A method of preparing spacerless carbon nanotubes for
drug delivery in the treatment of cancer comprising the
preparation of nanotubes in a biological buffer (50 mM)
in 8 ml of H20; adjusting the pH to 6.0 using IN NaOH
or IN HC1; taking 50 mM of EDC (1-ethyl -3(3-
dimethylainino propyl) carbodimide- mediator) in 1ml of
H20, and 50 mM of NHS (N-hydroxy succinimide-bear
ester) in 1ml of H20; adding EDC, followed by NHS to
buffer; adding Folic acid/cysteamine/ Fluorescein
Isothio- cyanate/PD98059 (DNA Inhibitor), Doxorubicin
(anti-cancer drug); stirring continuously for 6h; removing
the uncoupled drugs by washing thoroughly until pH-7.0
is reached; the EDC and NHS coupling to form urea
removed by washing.
2. A method of preparation of spacerless carbon
nanotubes for drug delivery in the treatment of cancer
substantially as herein described.
3. Spacerless carbon nanotubes for drug delivery in the
treatment of cancer whenever prepared in accordance